Tobramycin

CHEMBL1747 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

467.5 g/mol

LogP

-6.2

Phase

4

This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection). It can cause hearing loss and kidney damage, so levels in the blood must be monitored during intravenous use. The inhaled form is used to manage chronic lung infections in cystic fibrosis without the same level of systemic risk.

आणविक भार

467.5000 g/mol

LogP

-6.20

TPSA

268.00 Å²

लिपिंस्की RO5

अनुत्तीर्ण

चिकित्सीय क्षेत्र

अग्नाशय कैंसर अनिद्रा उच्च रक्तचाप ओवेरियन कैंसर कोलोरेक्टल कैंसर क्रॉनिक किडनी डिज़ीज़ ग्लूकोमा जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर थायरॉइड कैंसर दर्द प्रबंधन दीर्घकालिक दर्द नॉन-स्मॉल सेल लंग कैंसर प्रोस्टेट कैंसर बाइपोलर डिसऑर्डर माइग्रेन मिर्गी (एपिलेप्सी) मूत्राशय कैंसर संक्रामक रोग सिज़ोफ्रेनिया स्तन कैंसर हृदय विफलता

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O

InChI

InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

Molecular Formula

C18H37N5O9

HBD / HBA

10 / 14

घूर्णनीय बंधन

6

भारी परमाणु

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection). It can cause hearing loss and kidney damage, so levels in the blood must be monitored during intravenous use. The inhaled form is used to manage chronic lung infections in cystic fibrosis without the same level of systemic risk.

Yes, Tobramycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1747. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 36294. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Tobramycin PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C18H37N5O9
पर्यायवाची: 9

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.